Abstract 4097
Background
Neuregulin 1 (NRG1) is a growth factor that binds HER3/4 and activates ErbB signalling pathways. NRG1 fusions function as oncogenic drivers and represent a potential therapeutic target across tumour types. Afatinib, an ErbB-family blocker, may be a treatment option for some patients (pts) with NRG1 fusion-positive (NRG1+) tumours, as supported by preclinical evidence and published case reports (Table).Table: 1969P
Patient | Tumour type | NRG1 fusion partner | Best response | Duration of response (months) | Reference |
---|---|---|---|---|---|
i | Non-mucinous lung ADC | SLC3A2 | PR | 12 | Gay, et al. J Thoracic Oncol 2017 |
ii | Non-mucinous lung ADC | SDC4 | PR | 12 | Jones, et al. Ann Oncol 2017 |
iii | IMA | CD74 | PR | 10 | Gay, et al. J Thoracic Oncol 2017 |
iv | IMA | CD74 | PR | 6.5 | Cheema, et al. J Thoracic Oncol 2017 |
v | IMA | CD74 | SD | 3 | Drilon, et al. Cancer Discov 2018 |
vi | IMA | SDC4 | PD | - | Drilon, et al. Cancer Discov 2018 |
vii | IMA | CD74 | PD | - | Drilon, et al. Cancer Discov 2018 |
viii | Cholangiocarcinoma | ATP1B1 | PR | 8 | Jones, et al. Ann Oncol 2017 |
ix | Pancreatic ADC | ATP1B1 | PR | 3 | Heining, et al. Cancer Discov 2018 |
x | Ovarian cancer | CLU | SD | - | Murumagi. AACR 2019, abs 2945 |
ADC, adenocarcinoma; IMA, invasive mucinous lung adenocarcinoma; PD, progressive disease; PR, partial response; SD, stable disease
Methods
We report clinico-pathological and molecular characteristics of seven previously unreported cases of afatinib-treated NRG1+ tumours.
Results
Pt 1, 70 yo female, never-smoker with pan-wildtype, non-mucinous lung adenocarcinoma (ADC) received 15th-line afatinib for 24 mos (PR). An NRG1 fusion was subsequently identified. The pt was re-challenged with afatinib (PR, 3 mos) before switching to atezolizumab (PD). Pt 2, 66 yo female, never-smoker with metastatic (m) non-mucinous lung ADC. CD74-NRG1 fusion was identified, and 5th-line afatinib initiated. PR is ongoing after 14 mos. Pt 3, 68 yo male, >20 pack-yr smoking history with non-mucinous lung ADC. SDC4-NRG1 fusion was identified and 2nd-line afatinib initiated. Best response: SD, 4 mos. Pt 4, 43 yo female, non-smoker with advanced invasive mucinous lung ADC. CD74-NRG1 fusion was identified and 3rd-line afatinib initiated; PR is ongoing. Pt 5, 69 yo male, with KRAS-mutated m-colorectal cancer. Following a right hemicolectomy and liver/lung metastasectomies, a novel POMK-NRG1 fusion was detected and afatinib initiated (SD, 4 mos; treatment ongoing). Pts 6 and 7, male (54 & 59 yo) with KRAS WT, m-pancreatic cancers. Following PD on chemotherapy, APP-NRG1 and ATP1B1-NRG1 fusions, respectively, were detected and afatinib initiated. Pt 6 had a PR for 5 mos; treatment ongoing. Pt 7 had a PR for 5.5 mos.
Conclusions
These findings add to a growing body of evidence suggesting that afatinib is a potential treatment option for pts with NRG1+ tumours. Prospective study is ongoing in the Drug Rediscovery Protocol trial (DRUP; NCT02925234).
Clinical trial identification
N/A
Editorial acknowledgement
Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Christina Jennings, of GeoMed, an Ashfield company, part of UDG Healthcare plc.
Legal entity responsible for the study
Boehringer Ingelheim.
Funding
Boehringer Ingelheim.
Disclosure
S.V. Liu: Advisory / Consultancy: Apollomics; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Celgene; Advisory / Consultancy: G1 Therapeutics; Advisory / Consultancy: Genentech/Roche; Advisory / Consultancy: Heron; Advisory / Consultancy: Ignyta; Advisory / Consultancy: Janssen; Advisory / Consultancy: Lilly; Advisory / Consultancy: Regeneron; Advisory / Consultancy: Takeda/Ariad; Advisory / Consultancy: Tempus; Advisory / Consultancy: Merck; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Taiho. M. Duruisseaux: Honoraria (self): Roche; Honoraria (self): Takeda; Honoraria (self): Pfizer; Honoraria (self): Novartis; Honoraria (self): AstraZeneca; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Merck Sharp and Dohme; Honoraria (self): AbbVie; Honoraria (self): Boerhinger Ingelheim. K. Tolba: Advisory / Consultancy, Research grant / Funding (self): AstraZeneca; Advisory / Consultancy: Boerhinger Ingelheim; Honoraria (self): Merck; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Foundation One. Y. Goto: Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Eli Lilly; Advisory / Consultancy, Speaker Bureau / Expert testimony: Chugai; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Taiho Pharmaceuticals; Advisory / Consultancy, Speaker Bureau / Expert testimony: Boerhinger Ingelheim; Speaker Bureau / Expert testimony, Research grant / Funding (self): Ono Pharmaceuticals; Speaker Bureau / Expert testimony, Research grant / Funding (self): Bristol-Myers Squibb; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Pfizer; Speaker Bureau / Expert testimony: Merck Sharp and Dohme; Speaker Bureau / Expert testimony: Shionogi Pharmaceuticals; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Novartis; Advisory / Consultancy: GSK; Research grant / Funding (self): AbbVie; Research grant / Funding (self): Dai-ichi Sankyo; Advisory / Consultancy: Kyorin. B.A. Weinberg: Travel / Accommodation / Expenses: Boehringer Ingelheim. D.J. Renouf: Honoraria (self): Celgene; Honoraria (self): Servier; Honoraria (self): Taiho; Honoraria (self): Ipsen; Honoraria (self): Bayer. R.C. Doebele: Advisory / Consultancy, Shareholder / Stockholder / Stock options, Licensing / Royalties: Rain Therapeutics; Honoraria (self): Guardant; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Trovagene; Advisory / Consultancy, Licensing / Royalties: Ariad; Advisory / Consultancy: Takeda; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Genentech/Roche; Advisory / Consultancy, Research grant / Funding (self), Licensing / Royalties: Ignyta; Advisory / Consultancy, Research grant / Funding (self), Licensing / Royalties: Loxo; Research grant / Funding (self): Mirati; Licensing / Royalties: Abbott Molecular; Licensing / Royalties: GVKbio; Licensing / Royalties: Chugai; Licensing / Royalties: Genentech; Licensing / Royalties: Foundation Medicine; Licensing / Royalties: Black Diamond. R.F. Schlenk: Research grant / Funding (self): Boehringer Ingelheim. P.K. Cheema: Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Boehringer Ingelheim; Honoraria (self), Advisory / Consultancy: Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Takeda; Honoraria (self), Advisory / Consultancy: Genomic Health; Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self), Advisory / Consultancy: Merck. J. Cadranel: Advisory / Consultancy, Research grant / Funding (self): AstraZeneca; Advisory / Consultancy, Research grant / Funding (self): Boehringer Ingelheim; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Lilly; Advisory / Consultancy: Merck Sharp and Dohme; Advisory / Consultancy, Research grant / Funding (self): Novartis; Advisory / Consultancy, Research grant / Funding (self): Pfizer; Advisory / Consultancy: Roche; Advisory / Consultancy: Takeda. M.R. Jones: Full / Part-time employment: Qiagen Inc. A.E. Drilon: Honoraria (self): Medscape; Honoraria (self): OncLive; Honoraria (self): PeerVoice; Honoraria (self): Physicians Education Resources; Honoraria (self): Tyra Biosciences; Honoraria (self): Targeted Oncology; Honoraria (self): MORE Health; Honoraria (self): Research to Practice; Honoraria (self): Foundation Medicine; Honoraria (self): Peerview; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Genentech/Roche; Honoraria (self), Advisory / Consultancy: Bayer; Advisory / Consultancy: Ignyta; Honoraria (self): Loxo; Advisory / Consultancy: TP Therapeutics; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Blueprint Medicines; Advisory / Consultancy: Takeda; Advisory / Consultancy: Helsinn Therapeutics; Advisory / Consultancy: BeiGene; Advisory / Consultancy: Hengrui Therapeutics; Advisory / Consultancy: Exelixis; Travel / Accommodation / Expenses, Other: Wolters Kluwer. L.A. Muscarella: Honoraria (self): AstraZeneca; Honoraria (self): Roche; Honoraria (self): Boehringer Ingelheim. A. Cseh: Full / Part-time employment: Boehringer Ingelheim; Shareholder / Stockholder / Stock options, Husband: Mylan. F. Solca: Full / Part-time employment: Boehringer Ingelheim RCV GmbH & Co KG. J.J. Laskin: Honoraria (self), Research grant / Funding (self): Roche Canada; Honoraria (self): Boehringer Ingelheim Canada; Honoraria (self): AstraZeneca Canada; Research grant / Funding (self): Pfizer Canada. All other authors have declared no conflicts of interest.
Resources from the same session
4596 - A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis (MBM) (POLARIS)
Presenter: Michael Davies
Session: Poster Display session 3
Resources:
Abstract
1891 - Continuation of annual screening mammograms and breast-cancer mortality in women over 70
Presenter: Xabier Garcia De Albeniz
Session: Poster Display session 3
Resources:
Abstract
5587 - Introducing standardized medical procedure and dynamic decision support program in precision oncology for the community of practice
Presenter: Istvan Petak
Session: Poster Display session 3
Resources:
Abstract
4757 - Effectively using primary care givers in oncology care through capacity building, task sharing and techno-mentoring.
Presenter: Dinesh Pendharkar
Session: Poster Display session 3
Resources:
Abstract
4497 - A single institution review of capecitabine related acute admissions and cost analysis
Presenter: Gemma Dart
Session: Poster Display session 3
Resources:
Abstract
2187 - Health status of middle-aged and older cancer survivors in China: results from the China Health and Retirement Longitudinal Study (CHARLS)
Presenter: Jiarui Li
Session: Poster Display session 3
Resources:
Abstract
5101 - Crossed looks on lung cancer perception and knowledge from general public and physicians in France: results of a two-fold survey
Presenter: Céline Mascaux
Session: Poster Display session 3
Resources:
Abstract
4354 - Knowledge and perception of clinical trials (CTs) and attitude towards participation among Polish oncological patients - A pilot survey
Presenter: Artur Kotowski
Session: Poster Display session 3
Resources:
Abstract
3499 - Achieving best possible cancer treatment outcomes in care pathways through benchmarking; ABC-Benchmarking
Presenter: Anke Wind
Session: Poster Display session 3
Resources:
Abstract
2270 - Impact of 10-day Fulbright Specialist Program (FSP) and Project Pink Blue (PPB) Education Sessions on Medical Oncology knowledge among Doctors that treat cancer in Nigeria
Presenter: Mike Martin
Session: Poster Display session 3
Resources:
Abstract